Health Care • Biotechnology: Pharmaceutical Preparations
$174.00 ▼ -58.40
(-25.13%)
MKT CAP: $23.28B • VOL: 11.80M
52W L $163 52W H $480
ALNY // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.71B | $2.25B | $1.83B |
| YoY Revenue Growth % | +65.2% | +23.0% | — |
| Gross Profit | $3.04B | $1.94B | $804.4M |
| Gross Margin % | 81.8% | 86.4% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $501.6M | -$176.9M | -$282.2M |
| Operating Margin % | 13.5% | -7.9% | -15.4% |
| Net Income (GAAP) | $313.7M | -$278.2M | -$440.2M |
| EBITDA (Normalized) | $548.5M | -$149.5M | -$216.4M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $524.1M | -$8.3M | $104.2M |
| Capital Expenditures (CapEx) | $58.7M | $34.3M | $82.3M |
| Free Cash Flow (FCF) | $465.4M | -$42.6M | $21.9M |
| FCF Margin % | 12.5% | -1.9% | 1.2% |
| Return on Invested Capital (ROIC %) | 39.2% | -14.3% | -2.9% |
| Cash & Short-Term Equivalents | $1.66B | $966.4M | $1.41B |
| Total Debt (Short + Long Term) | $1.88B | $1.88B | $3.00B |
| Total Stockholders' Equity | $789.2M | $67.1M | $6.15B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ALNY.